Merck snaps up preclinical Lexington biotech for up to $773M
June 10, 2019 at 11:04 AM EDT
Tilos Therapeutics, a quiet preclinical biotech developing treatments for cancer and autoimmune diseases, has become the latest startup to be acquired by pharmaceutical giant Merck & Co.
